Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Bull: Johnson & Johnson successfully bridges its impending patent cliffs with high-margin pipeline approvals.
Talc Litigation Catastrophe: Settlements and ongoing liabilities breach the ring-fenced strategy, draining >$15B in free cash flow and triggering credit downgrades.
Johnson & Johnson is a mature, diversified healthcare compounder with wide competitive moats. Current market pricing heavily penalizes the stock for short-term litigation noise, creating a massive 49% upside gap to intrinsic value.
Johnson & Johnson is a mature, diversified healthcare compounder with wide competitive moats. Current market pricing heavily penalizes the stock for short-term litigation noise, creating a massive 49% upside gap to intrinsic value.
Extensive patent portfolio protecting high-margin immunology and oncology drugs.
High switching costs in MedTech (surgical equipment, orthopedics) due to physician training.
Aging global populations and rising chronic disease prevalence guarantee secular demand. Innovation cycles in oncology and robotics-assisted surgery drive premium pricing power.
A rare opportunity to acquire a pristine, wide-moat healthcare conglomerate at a steep discount to intrinsic value.
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
A severe stress test assumes complete loss of exclusivity on key blockbuster drugs without adequate pipeline replacement, compounded by a massive cash drain from talc litigation settlements. Operating margins compress to the low 20s, and the market violently re-rates the multiple to 12x, dropping the stock towards $150.
Intangible Assets: Extensive patent portfolio protecting high-margin immunology and oncology drugs.
Switching Costs: High switching costs in MedTech (surgical equipment, orthopedics) due to physician training.
Scale: Massive global distribution network and R&D budget ($14.6B in 2025) create insurmountable barriers for new entrants.
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Unavailable
FCFF DCF remains positive at the base case: base FCFF $29.9B after capex $5.2B, with terminal value at 74.2% of enterprise value. No FCF cliff is projected unless capex/ or materially resets.
If Innovative Medicine growth exceeds 5% organically -> multiple expands. If MedTech margins compress due to supply chain/fx -> minor earnings miss. If litigation settlement is finalized within current reserves -> massive relief rally.
If Innovative Medicine growth exceeds 5% organically -> multiple expands. If MedTech margins compress due to supply chain/fx -> minor earnings miss. If litigation settlement is finalized within current reserves -> massive relief rally.
If Innovative Medicine growth exceeds 5% organically -> multiple expands. If MedTech margins compress due to supply chain/fx -> minor earnings miss. If litigation settlement is finalized within current reserves -> massive relief rally.
If Innovative Medicine growth exceeds 5% organically -> multiple expands. If MedTech margins compress due to supply chain/fx -> minor earnings miss. If litigation settlement is finalized within current reserves -> massive relief rally.
Current cycle favors established players with bulletproof balance sheets capable of funding massive R&D ($14.6B) and strategic M&A to restock pipelines.
Aging global populations and rising chronic disease prevalence guarantee secular demand. Innovation cycles in oncology and robotics-assisted surgery drive premium pricing power.
Austerity measures in global healthcare budgets and aggressive IRA implementation in the US restrict reimbursement rates, punishing mature drug portfolios.
Current cycle favors established players with bulletproof balance sheets capable of funding massive R&D ($14.6B) and strategic M&A to restock pipelines.
Core portfolio holding.
Trim if the stock approaches the $330-$350 range where the valuation gap closes, or exit completely if free cash flow structurally declines below $15B annually.
Strong Buy. JNJ is a mature compounder suffering a massive, unjustified implied growth gap. Buy the structural cash flows while the market focuses on transient headline risks.
The private calibration is heavily distracted by short-term earnings noise and unquantified legal risks. Absolute cash flow models prove the market is severely undervaluing the long-term cash generation of the underlying IP and MedTech distribution moats.
Strong Buy. JNJ is a mature compounder suffering a massive, unjustified implied growth gap. Buy the structural cash flows while the market focuses on transient headline risks.
Reassess the thesis against the named valuation, risk, and quarterly checkpoint evidence in this report.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Generic erosion outpaces pipeline delivery, and regulatory pressure prevents price hikes. Continued legal overhang forces a sustained multiple discount, though the dividend and baseline FCF provide a hard floor around $244.
Settlements and ongoing liabilities breach the ring-fenced strategy, draining >$15B in free cash flow and triggering credit downgrades.
Biosimilar penetration accelerates faster than modeled, wiping out billions in high-margin revenue over 24 months with no pipeline offset.
Aggressive legislative action imposes strict price caps on top oncology/immunology assets, structurally impairing mature ROIC and terminal margins.
The five developments that would weaken our investment case.
Diminished cash conversion reduces internal funding available for dividend growth, share repurchases, and strategic acquisitions, weakening total shareholder return visibility.
Current:0.915 operating cash flow to net income ratio as of 2026-05-08
Alert ifFree cash flow conversion falls below 85.0% of net income over a trailing twelve-month period
Weakening medical device demand delays segment diversification, increasing dependence on pharmaceuticals and leaving earnings vulnerable to drug pricing headwinds.
Current:6.0% for the period ended 2025-12-31
Alert ifMedTech organic sales contract sequentially by more than 2.0% across two consecutive fiscal quarters
Escalating litigation settlements breach ring-fenced legal strategies and drain substantial balance sheet liquidity, prompting potential credit rating downgrades and constraining pipeline funding.
Current:$26.80B in net income for the period ended 2025-12-31
Alert ifFiled adverse legal judgments or settlement liabilities exceed existing reserves and drain more than $15B in cash over a 24-month period
Unmitigated loss of exclusivity on key blockbuster products shrinks high-margin revenue streams, permanently eroding structural gross profit without new therapeutic offset.
Current:67.9% gross margin for the period ended 2025-12-31
Alert ifBiosimilar revenue erosion on key commercial assets exceeds $2.0B annually without replacement pipeline approvals over a 24-month period
Sustained margin degradation indicates pricing concessions, inflationary cost pressures, or unfavorable business segment mix, ultimately depressing return on invested capital.
Current:27.2% for the period ended 2025-12-31
Alert ifConsolidated operating margin contracts below 25.0% for two consecutive fiscal quarters
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Project SBC-adjusted EPS, discount each year's earnings at cost of equity, then add a Gordon-growth terminal value.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Multiply the peer median PEG by this stock's forecast growth to derive an implied forward P/E, then apply it to forward EPS.
Discount the explicit dividend path and its Gordon-growth terminal value at cost of equity.
Solve for the growth rate that makes the model value equal the report-date share price.
Johnson & Johnson successfully bridges its impending patent cliffs with high-margin pipeline approvals. MedTech accelerates, and the market removes the litigation discount, rewarding the structural predictability with a premium multiple.
The core business continues to compound steadily. Cash flow models look past near-term litigation and generic erosion, correctly valuing the mature ROIC profile and durable competitive advantages.
Warning level: Free cash flow conversion falls below 85.0% of net income over a trailing twelve-month period. Diminished cash conversion reduces internal funding available for dividend growth, share repurchases, and strategic acquisitions, weakening total shareholder return visibility.
Warning level: MedTech organic sales contract sequentially by more than 2.0% across two consecutive fiscal quarters. Weakening medical device demand delays segment diversification, increasing dependence on pharmaceuticals and leaving earnings vulnerable to drug pricing headwinds.
Warning level: Filed adverse legal judgments or settlement liabilities exceed existing reserves and drain more than $15B in cash over a 24-month period. Escalating litigation settlements breach ring-fenced legal strategies and drain substantial balance sheet liquidity, prompting potential credit rating downgrades and constraining pipeline funding.
Warning level: Biosimilar revenue erosion on key commercial assets exceeds $2.0B annually without replacement pipeline approvals over a 24-month period. Unmitigated loss of exclusivity on key blockbuster products shrinks high-margin revenue streams, permanently eroding structural gross profit without new therapeutic offset.
Warning level: Consolidated operating margin contracts below 25.0% for two consecutive fiscal quarters. Sustained margin degradation indicates pricing concessions, inflationary cost pressures, or unfavorable business segment mix, ultimately depressing return on invested capital.
| $85.16B |
| $88.82B |
| $94.19B |
| +5.6% |
| Gross profit | $55.39B | $58.61B | $61.35B | $63.94B | +4.9% |
| Operating income | $19.64B | $15.83B | $17.44B | $33.55B | +19.6% |
| Net income | $17.94B | $35.15B | $14.07B | $26.80B | +14.3% |
| EPS (diluted) | $6.73 | $13.72 | $5.79 | $11.03 | +17.9% |
| EBITDA | $26.61B | $23.32B | $24.78B | $41.06B | +15.6% |
| R&D | $14.14B | $15.09B | $17.23B | $14.67B | +1.2% |
| SG&A | $20.25B | $21.51B | $22.87B | $23.68B | +5.4% |
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Revenue | 94,193,000,000 |
|---|---|
| Cost of revenue | 30,256,000,000 |
| Gross profit | 63,937,000,000 |
| Operating expenses | 38,341,000,000 |
| Operating income | 25,596,000,000 |
| Non-operating items and tax | 1,208,000,000 |
| Net income | 26,804,000,000 |
| Total assets | 199,210,000,000 |
|---|---|
| Cash | 19,709,000,000 |
| Current assets | 55,624,000,000 |
| Total liabilities | 117,666,000,000 |
| Current liabilities | 54,126,000,000 |
| Shareholders’ equity | 81,544,000,000 |
Point-in-time financial data used in the 2026-05-08 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-31 | 80B | 26.6B | 17.9B | 21.2B | 17.2B | 4B | 7B | 1.1B | 6B | 11.7B | 7.5B | — | — | — | — | 12.9B | 39.6B | 26.3% | — | — | — |
| 2023-12-31 | 85.2B | 23.3B | 35.2B | 22.8B | 17.8B | 5B | 7.5B | 1.2B | 5.1B | 11.8B | -2.7B | — | — | — | — | 21.9B | 29.3B | 25.8% | — | 6.3% | — |
| 2024-12-31 | 88.8B | 24.8B | 14.1B | 24.3B | 18.1B | 6.2B | 7.3B | 1.2B | 2.4B | 11.8B | 10.1B | — | — | — | — | 24.1B | 36.6B | 23.9% | — | 6.7% | — |
| 2025-12-31 | 94.2B | 41.1B | 26.8B | 24.5B | 19.3B | 5.2B | 7.5B | 1.4B | 6B | 12.4B | 9.6B | — | — | — | — | 19.7B | 47.9B | 27.2% | — | 6.4% | — |
JNJ trades at 17.5x forward earnings against a peer median of 13.9x; EV/EBITDA of 16.6x against a peer median of 13.2x; 6 peers.
| Level | Action |
|---|---|
| Thesis break | Trim if the stock approaches the $330-$350 range where the valuation gap closes, or exit completely if free cash flow structurally declines below $15B annually. |
| AbbVie Inc. |
| 12.5x |
| 5.7x |
| 14.2x |
| 62.2% |
| 31.6% |
| MRK | Merck & Co. Inc. | 11.8x | 4.2x | 11.0x | 18.9% | 38.6% |
| AMGN | Amgen Inc. | 14.0x | 4.8x | 13.2x | 101.3% | 33.8% |
| GILD | Gilead Sciences Inc. | 13.9x | 5.7x | 12.5x | 40.7% | 37.4% |
